Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

被引：0
|
作者：
Liang, Y. [1 ]
Krupsky, K. [2 ]
Lankin, J. [2 ]
Cohn, J. [2 ]
Kashine, N. [2 ]
Honomichl, R. [2 ]
Rattigan-Brown, Y. [1 ]
Shehu, A. [1 ]
Salomonsen, R. [1 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Oracle Life Sci, Austin, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
early-stage NSCLC; osimertinib; physician preferences;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.02
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [1] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [2] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
    Ferreira, Marion
    Ebia, Matthew I.
    Reckamp, Karen L.
    ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
  • [3] Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
    Patel, Shruti R.
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1631 - 1635
  • [4] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [5] Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case report
    Lasvergnas, Julie
    Monnet, Isabelle
    Auliac, Jean-Bernard
    Rousseau-Bussac, Gaelle
    Chouaid, Christos
    Assie, Jean-Baptiste
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (01) : 287 - 291
  • [6] MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Yan, D.
    Huelse, J.
    Parker, R.
    Wang, X.
    Frye, S.
    Earp, H. S.
    Deryckere, D.
    Graham, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1147 - S1147
  • [7] Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer
    Di Marino, Pietro
    Chiapperino, Cosima
    Primavera, Francesca Chiara
    Martino, Maria Teresa
    Brocco, Davide
    Carella, Consiglia
    Grassadonia, Antonino
    Tinari, Nicola
    De Tursi, Michele
    ONCOTARGETS AND THERAPY, 2022, 15 : 407 - 410
  • [8] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Kai Fu
    Fachao Xie
    Fang Wang
    Liwu Fu
    Journal of Hematology & Oncology, 15
  • [9] Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    EXPERT OPINION ON PHARMACOTHERAPY, 2025, : 491 - 501
  • [10] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Fu, Kai
    Xie, Fachao
    Wang, Fang
    Fu, Liwu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
12345